IL152908A0 - USE OF (+)-a- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL] -4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS - Google Patents

USE OF (+)-a- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL] -4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS

Info

Publication number
IL152908A0
IL152908A0 IL15290801A IL15290801A IL152908A0 IL 152908 A0 IL152908 A0 IL 152908A0 IL 15290801 A IL15290801 A IL 15290801A IL 15290801 A IL15290801 A IL 15290801A IL 152908 A0 IL152908 A0 IL 152908A0
Authority
IL
Israel
Prior art keywords
piperidinemethanol
dimethoxyphenyl
dementia
prodrug
fluorophenyl
Prior art date
Application number
IL15290801A
Other languages
English (en)
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of IL152908A0 publication Critical patent/IL152908A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
IL15290801A 2000-05-25 2001-05-23 USE OF (+)-a- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL] -4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS IL152908A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20694300P 2000-05-25 2000-05-25
PCT/US2001/016653 WO2001089498A2 (en) 2000-05-25 2001-05-23 USE OF (+)-α -(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS

Publications (1)

Publication Number Publication Date
IL152908A0 true IL152908A0 (en) 2003-06-24

Family

ID=22768607

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15290801A IL152908A0 (en) 2000-05-25 2001-05-23 USE OF (+)-a- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL] -4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS

Country Status (20)

Country Link
US (3) US20020099076A1 (es)
EP (1) EP1289527B1 (es)
JP (1) JP2003535058A (es)
KR (1) KR100784655B1 (es)
CN (1) CN1436078A (es)
AR (1) AR029666A1 (es)
AT (1) ATE390134T1 (es)
AU (2) AU6484201A (es)
BR (1) BR0111102A (es)
CA (1) CA2410554C (es)
DE (1) DE60133385T2 (es)
DK (1) DK1289527T3 (es)
ES (1) ES2300333T3 (es)
IL (1) IL152908A0 (es)
MX (1) MXPA02011511A (es)
NO (1) NO20025630L (es)
NZ (1) NZ522659A (es)
PT (1) PT1289527E (es)
TW (1) TWI299001B (es)
WO (1) WO2001089498A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ537629A (en) 2002-07-19 2007-05-31 Biovitrum Ab Novel piperazinyl-pyrazinone derivatives for the treatment of 5-HT2A receptor-related disorders
JP4975626B2 (ja) * 2004-09-30 2012-07-11 エフ．ホフマン−ラ ロシュ アーゲー 認知障害の処置用の組成物および方法
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
DE102006040278A1 (de) * 2006-08-21 2008-03-20 Technische Universität Dresden Arzneimittel zur Behandlung des Charles-Bonnet-Syndroms
SI3325444T1 (sl) 2015-07-20 2021-11-30 Acadia Pharmaceuticals Inc. Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
EP3436010B1 (en) * 2016-03-29 2021-03-10 Acadia Pharmaceuticals Inc. 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
WO2018200977A1 (en) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783471A (en) 1985-07-02 1988-11-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine methanol derivatives and the uses thereof
US4912117A (en) 1985-07-02 1990-03-27 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds
US5021428A (en) 1985-07-02 1991-06-04 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds for the prophylactic treatment of migraine
US5169096A (en) * 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
US4877798A (en) 1987-11-23 1989-10-31 Merrell Dow Pharmaceuticals Inc. Treatment of fibromyalgia
DE3888340T2 (de) 1988-01-21 1994-06-30 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
US5106855A (en) 1989-12-20 1992-04-21 Merrell Dow Pharmaceuticals Inc. Method for the treatment of glaucoma
US6004980A (en) 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
ATE114467T1 (de) * 1990-06-01 1994-12-15 Merrell Dow Pharma (+)-alpha-(2,3 dimethoxyphenyl)-1-(2- (fluorophenyl)ethyl>-4-piperidinmethanol.
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
FR2738819B1 (fr) * 1995-09-14 1997-12-05 Sanofi Sa Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
AU1118099A (en) * 1997-10-23 1999-05-10 Research Foundation Of The State University Of New York, The Methods of screening potential atypical antipsychotic drugs
WO2000012090A1 (en) 1998-08-28 2000-03-09 Aventis Pharmaceuticals Inc. THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS
CN1160333C (zh) * 1998-10-14 2004-08-04 阿温蒂斯药物公司 哌啶甲醇的酯和它们作为5ht2a受体拮抗剂mdl110907药物前体的用途
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same

Also Published As

Publication number Publication date
KR20030034078A (ko) 2003-05-01
PT1289527E (pt) 2008-05-13
PL359176A1 (en) 2004-08-23
US7132433B2 (en) 2006-11-07
DE60133385T2 (de) 2009-04-23
JP2003535058A (ja) 2003-11-25
WO2001089498A3 (en) 2002-05-10
ATE390134T1 (de) 2008-04-15
CA2410554A1 (en) 2001-11-29
NO20025630L (no) 2003-01-24
DE60133385D1 (de) 2008-05-08
EP1289527B1 (en) 2008-03-26
AU6484201A (en) 2001-12-03
WO2001089498A2 (en) 2001-11-29
NZ522659A (en) 2004-06-25
ES2300333T3 (es) 2008-06-16
KR100784655B1 (ko) 2007-12-12
TWI299001B (en) 2008-07-21
AR029666A1 (es) 2003-07-10
MXPA02011511A (es) 2003-04-25
BR0111102A (pt) 2003-03-11
US20040204457A1 (en) 2004-10-14
US20030036553A1 (en) 2003-02-20
EP1289527A2 (en) 2003-03-12
US20020099076A1 (en) 2002-07-25
CA2410554C (en) 2009-02-03
DK1289527T3 (da) 2008-07-14
NO20025630D0 (no) 2002-11-22
AU2001264842B2 (en) 2005-01-27
CN1436078A (zh) 2003-08-13

Similar Documents

Publication Publication Date Title
LU91280I2 (fr) Sorafenib et des sels pharmaceutiquement acceptables
GB2365772A (en) Factor
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
HUP0302772A3 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase
HUP0301773A3 (en) Apomorphine derivatives and methods for their use
IL152908A0 (en) USE OF (+)-a- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL) ETHYL] -4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS
WO2001056555A3 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2001265186A1 (en) Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
SI1197485T1 (en) Cyclobuten-dione derivatives for use in the treatment of artherosclerosis
SI1408964T1 (sl) Uporaba 2- 5-(4-fluorofenil)-3-piridilmetil-aminometil -kromana in njegovih fizioloĺ ko sprejemljivih soli
IL152388A0 (en) Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione
SI1299099T1 (sl) Nova uporaba (r)-(-)-2-5-(4-fluorofenil)-3-piridilmetilaminometil)-kromana in njegovih fiziolosko sprejemljivih soli
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
GB9802542D0 (en) New use
AU2001258714A1 (en) Herbal composition useful for treatment or oral cavity and method for its local delivery thereof
AU2525201A (en) Combination of cyamemazine and an atypical neuroleptic
HUP0202145A3 (en) The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders
AU2002211147A1 (en) Apparatus for making dental inlays and the like
HUP0300083A3 (en) Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
SI1289527T1 (sl) (+)-alfa-(2,3-dimetoksifenil)-1-(2-(4-fluorofenil)etil)-4- piperidinmetanol ali njegova predzdravila za zdravljenje demence ali kognitivne motnje
AU2001219672A1 (en) Phenoxyethyl-thiourea-pyridine compounds and their use for the treatment of hiv-infections
ZA989842B (en) Esters of (+)-Ó-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol.
AU782863C (en) The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
AU782870C (en) The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
SI1263745T1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one and use thereof for inhibiting hormone-sensitive lipase